Paper · 42577666
First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Liu Z and 3 others. Front Pharmacol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. Papers, record 42577666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42577666
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38,227,898 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38227898 | PubMed |
| 2 | 32,366,856 | anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/32366856 | PubMed |
| 3 | 36,270,461 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2022 | https://conductscience.org/library/papers/36270461 | PubMed |
| 4 | 33,082,645 | CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma. | Indian J Urol | 2020 | https://conductscience.org/library/papers/33082645 | PubMed |
| 5 | 35,466,428 | Direct and indirect regulation of the tumor immune microenvironment by VEGF. | J Leukoc Biol | 2022 | https://conductscience.org/library/papers/35466428 | PubMed |
| 6 | 39,706,335 | Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. | Ann Oncol | 2025 | https://conductscience.org/library/papers/39706335 | PubMed |
| 7 | 41,053,141 | Comparison of inflammatory and nutritional markers obtained at the time of diagnosis in patients diagnosed with renal cell carcinoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/41053141 | PubMed |
| 8 | 19,657,325 | The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. | Kidney Int | 2009 | https://conductscience.org/library/papers/19657325 | PubMed |
| 9 | 35,128,482 | Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. | Eur Urol Open Sci | 2022 | https://conductscience.org/library/papers/35128482 | PubMed |
| 10 | 38,289,361 | Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. | Cancer Immunol Immunother | 2024 | https://conductscience.org/library/papers/38289361 | PubMed |
1 to 10 of 54
See all 54 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KDR | 3,791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| VEGFA | 7,422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42577666
GET https://conductscience.org/api/papers/v1/42577666/references?page=2